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REASON FOR ERRATUM
In Table 2, the Median OS values (in
months) in the column ≥70 years were
changed due to a typesetting error. This
error does not change the scientific con-
clusions of the article in any way. The
publisher apologizes for this error and
the correct version of Table 2 appears
below.
Table 2 | Select efficacy outcomes from the Phase III trial of nab-paclitaxel plus carboplatin in NSCLC.
Treatment ITT (41) ≥70 years (42) Histology (43)
SCC NSCC
nab-P/C sb-P/C nab-P/C sb-P/C nab-P/C sb-P/C nab-P/C sb-P/C
n 514 524 74 82 229 221 292 310
ORR (%) 33 25 34 24 41 24 26 25
Response rate ratio 1.313 1.385 1.680 1.034
p-Value 0.005 0.196 <0.001 0.808
Median PFS (months) 6.3 5.8 8.0 6.8 5.6 5.7 6.9 6.5
HR 0.902 0.687 0.865 0.933
p-Value 0.214 0.134 0.245 0.532
Median OS (months) 12.1 11.2 19.9 10.4 10.7 9.5 13.1 13.0
HR 0.922 0.583 0.890 0.950
p-Value 0.271 0.009 0.284 0.611
HR, hazard ratio; IIT, intent-to-treat; nab-P/C, nab-paclitaxel+ carboplatin; NSCC, non-squamous cell carcinoma; NSCLC, non-small cell lung cancer; ORR, overall
response rate; OS, overall survival; PFS, progression-free survival; sb-P/C, solvent-based paclitaxel+ carboplatin; SCC, squamous cell carcinoma.
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